WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.Explore Efficacy
How can we help you?
Dosing for WELIREG
Information on dosing, including recommended dose reductions and dose modifications for adverse reactions.See Dosing Details
The Merck Access Program
For access and coverage information, visit The Merck Access Program.Visit Now